Your browser doesn't support javascript.
loading
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa, Shin; Ueda, Yasunori; Usuki, Kensuke; Kobayashi, Hajime; Kondo, Eisei; Doki, Noriko; Nakao, Takafumi; Kanda, Yoshinobu; Kosugi, Nobuharu; Kosugi, Hiroshi; Kumagai, Takashi; Harada, Hiroshi; Shikami, Masato; Maeda, Yasuhiro; Sakura, Toru; Inokuchi, Koiti; Saito, Akio; Nawa, Yuichiro; Ogasawara, Masahiro; Nishida, Junji; Kondo, Takeshi; Yoshida, Chikashi; Kuroda, Hiroyuki; Tabe, Yoko; Maeda, Yoshinobu; Imajo, Kenji; Kojima, Kensuke; Morita, Satoshi; Komukai, Sho; Kawaguchi, Atsushi; Sakamoto, Junichi; Kimura, Shinya.
Afiliación
  • Fujisawa S; Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
  • Ueda Y; Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Usuki K; Department of Hematology, NTT Medical Center, Tokyo, Japan.
  • Kobayashi H; Department of Hematology, Obihiro Kosei Hospital, Obihiro, Japan.
  • Kondo E; Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Doki N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Nakao T; Department of Hematology, Osaka City General Hospital, Osaka, Japan.
  • Kanda Y; Department of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
  • Kosugi N; Department of Hematology, Numazu City Hospital, Numazu, Japan.
  • Kosugi H; Department of Hematology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Kumagai T; Department of Hematology, Ome Municipal General Hospital, Ome, Japan.
  • Harada H; Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Shikami M; Department of Hematology, Daiyukai General Hospital, Ichinomiya, Japan.
  • Maeda Y; Department of Hematology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan.
  • Sakura T; Department of Hematology, Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Inokuchi K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Saito A; Department of Hematology, Fujioka General Hospital, Fujioka, Japan.
  • Nawa Y; Department of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Ogasawara M; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Nishida J; Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
  • Kondo T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Yoshida C; Department of Hematology, National Hospital Organization Mito Medical Center, Mito, Japan.
  • Kuroda H; Department of Gastroenterology and Hematology/Clinical Oncology, Steel Muroran Memorial Hospital, Muroran, Japan.
  • Tabe Y; Department of Next Generation Hematology Laboratory Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Maeda Y; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Imajo K; Department of Internal Medicine, Okayama Municipal Hospital, Okayama, Japan.
  • Kojima K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Komukai S; Division of Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Kawaguchi A; Division of Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Sakamoto J; Tokai Central Hospital, Kakamigahara, Japan.
  • Kimura S; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. shkimu@cc.saga-u.ac.jp.
Int J Clin Oncol ; 24(4): 445-453, 2019 Apr.
Article en En | MEDLINE | ID: mdl-30421023
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Japón